Core Viewpoint - Revive Therapeutics Ltd. has successfully closed the first tranche of its private placement offering, raising a total of $60,900 through the issuance of 2,900,000 units at a price of $0.021 per unit, while also settling a note payable through the issuance of additional units [1][2][3]. Group 1: Offering Details - The first tranche of the offering consisted of 2,900,000 units, generating gross proceeds of $60,900 for the company [1]. - Each unit comprises one common share and one common share purchase warrant, with the warrant allowing the holder to acquire one common share at an exercise price of $0.05 for 36 months [2]. - The company issued an additional 3,209,523 units to settle a note payable of $67,400, maintaining the same issue price of $0.021 per unit [1][3]. Group 2: Use of Proceeds - The gross proceeds from the offering will be allocated for working capital and the payment of certain trade payables [2]. Group 3: Compensation Options - In connection with the offering, the company issued 100,000 compensation options to an investment dealer, allowing the dealer to purchase units at a price of $0.05 for 18 months [4]. - Each compensation unit consists of one common share and one-half of a common share purchase warrant, with the whole warrant allowing acquisition of one compensation share at an exercise price of $0.05 for 36 months [5]. Group 4: Company Overview - Revive Therapeutics is focused on developing innovative therapeutics for critical medical needs, leveraging FDA regulatory incentives for rapid advancement and market entry [6]. - The company is currently concentrating on the potential of Bucillamine for infectious diseases and medical countermeasures, as well as advancing its Psilocybin and molecular hydrogen therapeutic programs [6].

Core Viewpoint - Revive Therapeutics Ltd. is proposing a private placement offering of up to 30,952,381 units at a price of $0.021 per unit, aiming for gross proceeds of up to $650,000, while also settling a note payable of $67,400 through the issuance of additional units at the same price [1][3]. Group 1: Private Placement Details - The private placement will consist of units, each comprising one common share and one common share purchase warrant, with warrants allowing the purchase of one common share at an exercise price of $0.05 for 36 months post-closing [2]. - The gross proceeds from the offering will be allocated for working capital and settling certain trade payables, with the potential for the placement to close in multiple tranches [3]. Group 2: Closing Conditions and Securities - The closing of the private placement and debt settlement is subject to customary closing conditions, with the company intending to close as soon as practicable [4]. - All securities issued will be subject to a hold period of four months and one day from the issuance date [4]. Group 3: Company Overview - Revive Therapeutics is focused on developing innovative therapeutics for critical medical needs, prioritizing its drug development pipeline to leverage FDA regulatory incentives for rapid advancement and market entry [5]. - Current efforts are concentrated on the potential of Bucillamine for infectious diseases and medical countermeasures, alongside advancing Psilocybin and molecular hydrogen therapeutic programs [5].